BioSpace News Archive

Helius Medical Technologies, Inc. announced that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, will present at the 35th Annual ROTH Conference, March 12-14, 2023, Laguna Nigel, CA, as follows:

X4 Pharmaceuticals announced that, effective on February 28, 2023, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

Quoin Pharmaceuticals Ltd. announced that the Company intends to release its 2022 fourth quarter and year-end financial results after the market closes on Wednesday, March 8, 2023.

Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced that management will present and be available for 1x1 meetings at Oppenheimer’s 33rd Annual Healthcare Conference taking place virtually on March 13-15, 2023.

Confo Therapeutics, a leader in the discovery of medicines targeting G-protein coupled receptors, announced a worldwide licensing agreement with Eli Lilly and Company for Confo’s clinical stage CFTX-1554 and back-up compounds.

Haemonetics Corporation has announced that it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) on the next-generation software for the Cell Saver ® Elite ® + Autotransfusion System.

uniQure N.V. today announced its participation in the following upcoming investor and scientific conferences.

Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2022 and provided an operational update.

Sernova Corp. today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheimer 33rd Annual Healthcare Conference, taking place March 13-15, 2023. Company management will also be participating in one-on-one investor meetings at the conferences.

Medicenna Therapeutics Corp. today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a fireside chat at the Oppenheimer 33rd Annual Healthcare Conference, which is scheduled to take place virtually from March 13 – 15, 2023.